Skip to content
GLP-1 Desk
Menu
Dispatch #5Editorial

Vytora Health

Low flat pricing on both molecules with brand access and full nationwide reach — value without the state limits.

Visit Vytora HealthEditorial — no commercial relationship.
Semaglutide
$150/mo
Tirzepatide
$200/mo
Coverage
All 50 states
Brand-name
Yes

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency90/100
State access96/100
Molecule range90/100
Onboarding speed84/100
Support responsiveness82/100
Licensing & trust90/100

What the Desk likes

  • Low pricing on both semaglutide and tirzepatide
  • Brand-name access available
  • Nationwide 50-state coverage

Where points come off

  • Injectable only — no oral route
  • Shorter operating history than legacy brands

The Desk's briefing — A−

Best for: Budget-minded patients who want brand access and all-50-state coverage in one place.

Vytora Health ranks #5 of 25 providers scored — see #1, CoreAge Rx on the board.

Related dispatches

Pricing and verification reflect Vytora Health's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Vytora Health's site. Not medical advice; see our disclosure.

← Back to The Desk